Cellectis (NASDAQ: CLLS, Euronext Growth: ALCLS) announced it will report its second quarter 2026 financial results, for the period ended June 30, 2026, on Thursday, August 6, 2026 after the close of the US market. The earnings press release will be available in the Investors section of the company’s website.
Cellectis noted it will not host a conference call to discuss these results. Investor questions can be directed to the company’s investor relations team at investors@cellectis.com. Cellectis is a clinical-stage biotechnology company focused on allogeneic CAR T immunotherapies and gene therapies, with headquarters in Paris and additional locations in New York and Raleigh.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The two prior earnings-date notices were followed by 1.62% and 2.7% moves, framing this scheduling a...
Analysis
The two prior earnings-date notices were followed by 1.62% and 2.7% moves, framing this scheduling announcement within a positive historical pattern. The August 6 results release is the next checkpoint, with an effective F-3 shelf as a financing risk.
Scheduled fourth-quarter and full-year 2025 results with follow-up investor conference call
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Both prior earnings-date announcements were followed by positive 24-hour price reactions.
Key Terms
gene-editing, allogeneic, car t, off-the-shelf
4 terms
gene-editingtechnical
"using its pioneering gene-editing platform to develop life-saving cell and gene therapies"
Gene-editing is a set of laboratory techniques that change an organism’s DNA by adding, removing or altering specific genetic instructions—think of it as editing words in a document to fix a sentence. For investors, it matters because these tools can create new treatments, improve agricultural crops or reduce manufacturing costs, potentially driving product value, regulatory risk, research milestones and long-term revenue prospects for companies involved.
allogeneicmedical
"The company utilizes an allogeneic approach for CAR T immunotherapies"
Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.
car tmedical
"allogeneic approach for CAR T immunotherapies in oncology"
CAR T is a type of immunotherapy that reprograms a patient’s own white blood cells to recognize and attack cancer cells, like giving immune cells a custom GPS to find and destroy tumors. It matters to investors because CAR T therapies can offer durable responses for hard-to-treat cancers, but they also involve complex manufacturing, high costs, regulatory hurdles and market access challenges that affect a company’s revenue potential and risk profile.
off-the-shelfmedical
"pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells"
Off-the-shelf describes products, software, medical devices, or solutions that are commercially available and ready to use without custom design or development. Investors care because off-the-shelf items typically cost less and reach the market faster than bespoke alternatives, reducing project risk and expense; like buying a ready-made appliance instead of commissioning a custom-built one, they offer predictable performance and clearer regulatory and cost forecasts.
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.
Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at investors@cellectis.com
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact: Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
When will Cellectis (CLLS) report its Q2 2026 financial results?
Cellectis will report its Q2 2026 financial results on August 6, 2026 after the US market close. According to Cellectis, the press release will cover the quarter ended June 30, 2026 and be posted on its investor website.
Will Cellectis (NASDAQ: CLLS) hold an earnings call for Q2 2026 results?
Cellectis will not host a conference call for its Q2 2026 results. According to Cellectis, investors and analysts may instead contact the investor relations team directly at investors@cellectis.com with questions about the announced financial information.
Where can investors find Cellectis Q2 2026 earnings press release?
The Cellectis Q2 2026 earnings press release will be available in the Investors section of the company’s website. According to Cellectis, it will be posted after results are released on August 6, 2026 following the US market close.
How can investors contact Cellectis (CLLS) investor relations about Q2 2026 results?
Investors can contact Cellectis investor relations by emailing investors@cellectis.com. According to Cellectis, the investor relations team will be available to answer questions related to the Q2 2026 financial results and other shareholder inquiries.
On which exchanges is Cellectis (CLLS, ALCLS) listed for investors?
Cellectis is listed on the Nasdaq Global Market under ticker CLLS and on Euronext Growth under ticker ALCLS. According to Cellectis, these listings give investors access to the stock in US and European markets.
What type of company is Cellectis ahead of its Q2 2026 earnings date?
Cellectis is a clinical-stage biotechnology company focused on gene editing for cell and gene therapies. According to Cellectis, it develops allogeneic CAR T immunotherapies and other gene therapies, supported by in-house manufacturing and sites in Paris, New York, and Raleigh.
